- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00055653
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic disorders.
Study Overview
Status
Detailed Description
OBJECTIVES:
- Determine 180-day survival in patients with malignant or nonmalignant hematologic diseases treated with allogeneic umbilical cord blood transplantation. (Severe aplastic anemia, Fanconi anemia, and marrow failure syndromes strata are closed to accrual; adult [over 18 years of age] patient stratum is closed to accrual.)
- Determine disease-free and long-term survival in patients treated with this regimen.
- Determine the incidence of neutrophil engraftment, primary and secondary graft failure, platelet engraftment, and red blood cell engraftment in patients treated with this regimen.
- Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen.
- Determine the incidence of complications, including infection, veno-occlusive disease, and interstitial pneumonitis, in patients treated with this regimen.
- Determine the incidence of relapse, other malignancies, lymphoproliferative disorders, and posttransplantation myelodysplasia in patients treated with this regimen.
- Determine the immune reconstitution in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are grouped according to the following strata:
- Stratum I: Malignant disease, 5/6 or 6/6 HLA match, age 18 and under
- Stratum II: Malignant disease, 4/6 HLA match, age 18 and under
- Stratum III: Malignant disease, 3/6 HLA match, age 18 and under
- Stratum IV: Malignant disease, 2/6 or 1/6 HLA match, age 18 and under
- Stratum V (closed to accrual): Severe aplastic anemia, Fanconi anemia, or other marrow failure syndrome
- Stratum VI: Inborn errors of metabolism/storage diseases and other nonmalignant diseases not included in stratum V
- Stratum VII: Malignant disease receiving alternative conditioning regimen comprising busulfan and melphalan
- Stratum VIII (closed to accrual): Adult patients (over age 18)
Conditioning therapy: Patients are assigned to 1 of 5 groups according to diagnosis.
- Group I (malignant disease or severe aplastic anemia [severe aplastic anemia closed to accrual]): Patients undergo total body irradiation (TBI) once or twice daily on days -8 to -4. Patients then receive cyclophosphamide IV on days -3 and -2, methylprednisolone IV on days -3 to 0, and antithymocyte globulin (ATG) IV once or twice daily on days -3 to -1.
- Group II (Fanconi anemia [closed to accrual]): Patients undergo TBI on day -6, and then receive cyclophosphamide IV and fludarabine IV on days -5 to -2, and methylprednisolone IV and ATG IV on days -5 to -1.
- Group III (inborn errors of metabolism/storage disease): Patients receive oral busulfan 4 times daily on days -9 to -6, cyclophosphamide as in group II, and methylprednisolone and ATG as in group I.
- Group IV (other nonmalignant diseases): Patients receive conditioning therapy as in group III. Patients with familial erythrophagocytic lymphohistiocytosis or Langerhans cell histiocytosis also receive etoposide on days -5 to -3.
- Group V (non-TBI regimen for leukemia patients under 2 years of age): Patients receive oral busulfan 4 times daily on days -8 to -5, melphalan IV on days -4 to -2, and methylprednisolone and ATG as in group I.
- Allogeneic umbilical cord blood transplantation: All patients undergo umbilical cord blood transplantation on day 0. Beginning on day 0 or 1, patients receive filgrastim (G-CSF) IV or subcutaneously daily until blood counts recover.
- Graft-versus-host disease prophylaxis: Patients receive cyclosporine (IV or oral) beginning between days -3 and -1 and continuing for 1 year after transplantation and methylprednisolone twice daily beginning on day 1 and continuing until blood counts recover.
Patients are followed weekly for 14 weeks, at 100 days, and at 4, 5, 6, 9, 12, 18, 24, and 36 months.
PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
Los Angeles, California, United States, 90027-0700
- Children's Hospital Los Angeles
-
Orange, California, United States, 92868
- Children's Hospital of Orange County
-
San Francisco, California, United States, 94143-1278
- Children's Medical Center, University of California San Francisco
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010-2970
- Children's National Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5289
- Indiana University Cancer Center
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70118
- Children's Hospital of New Orleans
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Spectrum Health and DeVos Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Cancer Center
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Children's Mercy Hospital
-
Saint Louis, Missouri, United States, 63104-1095
- Cardinal Glennon Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, United States, 14263-0001
- Roswell Park Cancer Institute
-
Manhasset, New York, United States, 11030
- North Shore University Hospital
-
Rochester, New York, United States, 14642
- James P. Wilmot Cancer Center at University of Rochester Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke Comprehensive Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44106-5065
- Ireland Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232-6310
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, United States, 75230
- Medical City Dallas Hospital
-
Dallas, Texas, United States, 75235
- Children's Medical Center of Dallas
-
San Antonio, Texas, United States, 78229
- Texas Transplant Institute
-
-
Washington
-
Seattle, Washington, United States, 98109-1024
- Fred Hutchinson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following hematologic malignancies:
Acute myeloid leukemia (AML)*
- With or without history of myelodysplastic syndromes (MDS)
- Patients in first complete remission (CR) (no greater than 5% blasts in marrow) with translocations t(8;21) and inv(16) are allowed provided they failed first-line induction therapy
Patients in first CR (no greater than 5% blasts in marrow) with translocations t(15;17) are allowed provided at least 1 of the following is true:
- Failed first-line induction therapy
- Molecular evidence of persistent disease
- No patients in first CR and with Down syndrome
Acute lymphoblastic leukemia (ALL)*, meeting 1 of the following criteria:
- Not in first CR (no greater than 5% blasts in marrow)
In first CR and high risk as defined by 1 of the following:
- Hypoploidy (no more than 44 chromosomes)
- Pseudodiploidy with translocations or molecular evidence of t(9;22), 11q23, or t(8;14) (excluding B-ALL) or +MLL gene rearrangement
One of the following elevated WBC levels:
- WBC greater than 100,000/mm^3 if 6 to 12 months of age
- WBC greater than 200,000/mm^3 if between 10 and 17 years of age
- WBC greater than 20,000/mm^3 if 18 years of age and over (adult [over 18 years of age] patient stratum closed to accrual)
- Failed to achieve CR after 4 weeks of induction therapy
B-ALL that is not in first CR or that meets at least 1 of the high-risk criteria specified above
- No translocation t(8;14)
- No blasts with surface immunoglobulins
- CD10 negative
- Undifferentiated leukemia*
- Infant leukemia*
- Biphenotypic leukemia*
Chronic myelogenous leukemia, meeting 1 of the following criteria:
- Accelerated phase
Chronic phase
- At least 1 year from diagnosis without an identified matched unrelated bone marrow donor AND unresponsive to or unable to tolerate interferon
- Blast crisis* (greater than 30% promyelocytes plus blasts in the marrow)
One of the following MDS:
- Refractory anemia
- Refractory anemia with ringed sideroblasts
- Refractory anemia with excess blasts (RAEB)
- RAEB in transformation
- Chronic myelomonocytic leukemia
- Paroxysmal nocturnal hemoglobinuria
Hodgkin's or non-Hodgkin's lymphoma beyond first CR or failed primary induction therapy
- Tumor displays chemosensitivity (greater than 50% reduction in mass size after the most recent therapy) NOTE: *Patients in third or greater medullary relapse or refractory disease (other than primary induction failures) or blast crisis receive the study busulfan/melphalan conditioning regimen)
OR
Diagnosis of one of the following nonmalignant diseases :
Acquired severe aplastic anemia (stratum closed to accrual)
- Unresponsive to medical therapy with anti-thymocyte globulin and/or cyclosporine
Inborn errors of metabolism, including, but not limited to the following:
- Hurler's syndrome
- Adrenoleukodystrophy
- Maroteaux-Lamy syndrome
- Globoid cell leukodystrophy
- Metachromatic leukodystrophy
- Fucosidosis
- Mannosidosis
Fanconi anemia documented by increased chromosomal fragility assays and meeting 1 of the following criteria (stratum closed to accrual):
Severe pancytopenia
- Absolute neutrophil count less than 500/mm^3
- Platelet count less than 20,000/mm^3
- Hemoglobin less than 8 g/dL
- Morphologic evidence of MDS with clonal chromosomal abnormalities
- Leukemia transformation
Other marrow failure syndromes, including any of the following (stratum closed to accrual):
- Blackfan-Diamond syndrome that is unresponsive to medical therapy
- Kostmann's congenital agranulocytosis unresponsive to medical therapy
- Congenital amegakaryocytic thrombocytopenia
- Thrombocytopenia absent radius
Combined immune deficiencies including, but not limited to the following:
- Severe combined immunodeficiency (SCID)
- Wiskott-Aldrich syndrome
- Leukocyte adhesion defect
- Chediak-Higashi disease
- X-linked lymphoproliferative disease
- Adenosine deaminase deficiency
- Purine nucleoside phosphorylase deficiency
- X-linked SCID
- Common variable immune deficiency
- Nezeloff's syndrome
- Cartilage hair hypoplasia
- Reticular dysgenesis
- No active CNS leukemia (cerebrospinal fluid with WBC greater than 5/mm^3 and malignant cells on cytospin)
- No SCID patients who do not require cytoreduction
- No dyskeratosis congenita
- No primary myelofibrosis
- No grade 3 or greater myelofibrosis
Familial erythrophagocytic lymphohistiocytosis patients must not have any of the following:
- Abnormal brain MRI
- Neurologic symptoms
- Lymphocytes and monocytes greater than 7/mm^3 in the cerebrospinal fluid
- No available 5/6 or 6/6 HLA-matched related donor
PATIENT CHARACTERISTICS:
Age
- 55 and under (over 18 closed to accrual)
Performance status
- Karnofsky 70-100% OR
- Lansky 50-100% (patients under 16 years old)
Life expectancy
- Not specified
Hematopoietic
- See Disease Characteristics
Hepatic
- SGOT less than 5 times upper limit of normal
- Bilirubin less than 2.5 mg/dL
Renal
- Creatinine normal for age OR
- Creatinine clearance or glomerular filtration rate greater than 50% of lower limit of normal
Cardiovascular
- LVEF greater than 40% at rest and must improve with exercise* OR
- Shortening fraction greater than 26%* NOTE: *If symptomatic
Pulmonary
- DLCO greater than 45% of predicted* (corrected for hemoglobin)
- FEV_1 and FEC greater than 45% of predicted (corrected for hemoglobin) OR
- Room air oxygen saturation greater than 85%* NOTE: *If symptomatic
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No uncontrolled viral, bacterial, or fungal infection
- HIV negative
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- More than 12 months since prior allogeneic stem cell transplantation with cytoreductive preparative therapy
- More than 6 months since prior autologous stem cell transplantation
Chemotherapy
- See Biologic therapy
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Other
- No prior enrollment on this study
- No continuous life support (e.g., mechanical ventilation) within 1 year after study transplantation (for patients with inborn errors of metabolism)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Philip L. McCarthy, MD, Roswell Park Cancer Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- recurrent childhood small noncleaved cell lymphoma
- recurrent childhood large cell lymphoma
- refractory anemia
- refractory anemia with ringed sideroblasts
- refractory anemia with excess blasts
- refractory anemia with excess blasts in transformation
- chronic myelomonocytic leukemia
- de novo myelodysplastic syndromes
- previously treated myelodysplastic syndromes
- secondary myelodysplastic syndromes
- secondary acute myeloid leukemia
- childhood acute lymphoblastic leukemia in remission
- childhood acute myeloid leukemia in remission
- chronic phase chronic myelogenous leukemia
- atypical chronic myeloid leukemia
- myelodysplastic/myeloproliferative disease, unclassifiable
- untreated childhood acute lymphoblastic leukemia
- recurrent/refractory childhood Hodgkin lymphoma
- blastic phase chronic myelogenous leukemia
- recurrent childhood acute lymphoblastic leukemia
- accelerated phase chronic myelogenous leukemia
- recurrent childhood acute myeloid leukemia
- recurrent childhood lymphoblastic lymphoma
- acute undifferentiated leukemia
- untreated childhood acute myeloid leukemia and other myeloid malignancies
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Lymphoma
- Syndrome
- Myelodysplastic Syndromes
- Leukemia
- Preleukemia
- Myeloproliferative Disorders
- Myelodysplastic-Myeloproliferative Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Neuroprotective Agents
- Protective Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Dermatologic Agents
- Antifungal Agents
- Calcineurin Inhibitors
- Methylprednisolone
- Cyclophosphamide
- Melphalan
- Fludarabine
- Fludarabine phosphate
- Busulfan
- Antilymphocyte Serum
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
- CDR0000270487
- RPCI-DS-00-22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
Clinical Trials on cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted